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Abstract
Background: Coffee consumption has been associated with a lower risk of type 2 diabetes in prospective cohort
studies, but the underlying mechanisms remain unclear. The aim of this study was to evaluate the effects of
regular and decaffeinated coffee on biological risk factors for type 2 diabetes.
Methods: Randomized parallel-arm intervention conducted in 45 healthy overweight volunteers who were
nonsmokers and regular coffee consumers. Participants were assigned to consumption of 5 cups (177 mL each)
per day of instant caffeinated coffee, decaffeinated coffee, or no coffee (i.e., water) for 8 weeks.
Results: Average age was 40 years and body mass index was 29.5 kg/m
2. Compared with consuming no coffee,
consumption of caffeinated coffee increased adiponectin (difference in change from baseline 1.4 μg/mL; 95% CI:
0.2, 2.7) and interleukin-6 (difference: 60%; 95% CI: 8, 138) concentrations and consumption of decaffeinated coffee
decreased fetuin-A concentrations (difference: -20%; 95% CI: -35, -1). For measures of glucose tolerance, insulin
sensitivity, and insulin secretion, no significant differences were found between treatment groups.
Conclusions: Although no changes in glycemia and/or insulin sensitivity were observed after 8 weeks of coffee
consumption, improvements in adipocyte and liver function as indicated by changes in adiponectin and fetuin-A
concentrations may contribute to beneficial metabolic effects of long-term coffee consumption.
Trial Registration: clinicaltrials.gov NCT00305097
Introduction
Coffee consumption has been associated with a substan-
tially lower risk of type 2 diabetes mellitus (T2DM) in
prospective cohort studies in the United States (US),
Europe, and Asia [1,2]. Paradoxically, caffeine intake
acutely reduced insulin sensitivity and glucose tolerance
in short-term trials [3]. Data on the effects of coffee
intake on glucose metabolism from randomized trials
lasting more than 24 hours are sparse and limited to
effects on fasting glucose and insulin concentrations [4].
In addition to caffeine, coffee contains hundreds of
components and decaffeinated coffee, chlorogenic acid,
quinides, lignans, and trigonelline significantly improved
insulin sensitivity or glucose levels in animal studies
[5-7].
In cross-sectional studies, coffee consumption has
been associated with higher adiponectin concentrations,
lower concentrations of inflammatory markers, and
lower levels of markers of liver damage [8,9]. In a recent
non-randomized trial, increases in coffee consumption
were also associated with increases in adiponectin levels
[10]. Higher adiponectin levels have been consistently
associated with a lower risk of T2DM possibly reflecting
anti-inflammatory and insulin sensitizing effects [11].
Fetuin-A, a biomarker for inflammation and liver func-
tion, is a glycoprotein secreted by the hepatocytes with
effects on insulin signaling via inhibition of the insulin
receptor tyrosine kinase in both liver and skeletal tissue
[12]. Higher fetuin-A levels have been associated with
insulin resistance and a higher risk of T2DM [13,14].
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have also been implicated in the development of insulin
resistance [15].
To our knowledge, the effects of regular and decaffei-
nated coffee consumption on adiponectin, fetuin-A, and
inflammatory markers have not been studied in rando-
mized controlled trials. We therefore conducted an 8-
week parallel-arm randomized trial to determine the
effects of caffeinated and decaffeinated coffee on risk
factors for T2DM.
Research design and methods
Study Participants
The study was conducted between May 2006 and Sep-
tember 2008. Participants were volunteers recruited
from the community and were deemed eligible to parti-
cipate if they were regular coffee consumers (≥ 2c u p s /
day), nonsmokers, aged 18 years or older, and over-
weight (body mass index (BMI) 25-35 kg/m
2), but other-
wise healthy according to a detailed screening that
included a medical history, physical examination, elec-
trocardiogram, and laboratory tests. Participants were
excluded if they had diabetes mellitus (fasting blood glu-
cose ≥ 7 mmol/L), heart disease, stroke, hypertension
(blood pressure > 140 mmHg/90 mmHg or antihyper-
tensive medications), alcoholism, drug abuse, abnormal
hepatic function (transaminases > twice the upper limit
of normal), abnormal renal function (creatinine > 97.2
μmol/L), malabsorption syndromes, gastro-esophageal
reflux disease or a history of ulcer. We also excluded
individuals on medications with potential interactions
with caffeine or that might impact study results, and
women who were breastfeeding or planning a
pregnancy.
Of the 65 individuals that participated in the screen-
ing, 11 did not qualify to participate and 9 withdrew
consent prior to randomization. Of the remaining 45
individuals, three participants discontinued between the
baseline and 4-week visits, and one participant dropped
out after the 4-week visit (See Additional file 1, figure
s1). The study was approved by the institutional review
boards of the Beth Israel Deaconess Medical Center and
the Harvard School of Public Health and all participants
provided written informed consent to participate. The
clinical trial registration number is NCT00305097.
Study Design
Participants were counseled by a research dietitian prior
to starting the study and asked to abstain from coffee
and caffeine-containing foods for the duration of the
study (except for the coffee provided as part of the
treatment regimen) and received a list of caffeine con-
taining foods and beverages to avoid. After two weeks of
caffeine washout and after an overnight fast (minimum
12 hours), participants attended the clinical research
center for baseline assessment. Physical examination and
baseline blood draw were performed followed by an oral
glucose tolerance test (OGTT).
At this visit, participants were randomly assigned by a
blinded statistician using a randomization schedule gen-
erated via the PROC PLAN procedure in the Statistical
Analysis System 9.1 (SAS Institute Inc., NC, US). The
treatment allocation was 1:1:1 (caffeinated coffee: decaf-
feinated coffee: no coffee) in block sizes of six with stra-
tification by sex. A surrogate randomization list was
generated and validated by the randomization statisti-
cian. Participants, investigators, and laboratory staff
were blinded regarding the treatment assignment for the
caffeinated and decaffeinated coffee arms.
Participants were asked to maintain stable exercise
and dietary habits throughout the study and were asked
to keep 3-day food diaries (1 weekend day and 2 week-
days) prior to each visit. Participants returned for repeat
assessments after four weeks and 8 weeks. Participants
were assessed for changes in medications or health sta-
tus, for side-effects of coffee and for adherence to the
intervention by questionnaires. Participants had an addi-
tional non-fasting visit at 6 weeks (typically scheduled
between 12-2 pm) for a blood draw to measure serum
caffeine concentrations for compliance assessment.
Intervention
Participants who were assigned to one of the two coffee
arms of the study were provided with five pre-weighed
two-gram portions of instant coffee per day (caffeinated
or decaffeinated Nestlé’sT a s t e r ’sC h o i c e
®). They were
instructed to prepare the coffee with 6 ounces (177 mL)
of boiling water and to consume coffee five times per
day with every meal, and at mid-morning and mid-after-
noon. Participants who reported using sugar in their
coffee were provided with a non-caloric sweetener and
participants had the choice of using a non-dairy crea-
mer, which was also provided. Participants who were
randomized to the control (no coffee) intervention were
instructed to consume five 6-ounce glasses of water also
with every meal, and at mid-morning and mid-
afternoon.
Caffeine content of the coffee was measured at Tufts
University School of Medicine (Boston, MA, US).
Chlorogenic acid was measured at the RIKILT Institute
of Food Safety (Wageningen, The Netherlands) as pre-
viously described [16]. Trigonelline content was mea-
sured in quadruplicate at the Canterbury Health
Laboratories (Christchurch, New Zealand) using meth-
ods described by Lever et al. [17]. The caffeine concen-
tration in the prepared regular coffee was 344 μg/mL.
Chlorogenic acid and trigonelline were measured both
in samples kept at room temperature during the study
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ning of the study. Chlorogenic acid concentrations were
34 mg/g (frozen: 33 mg/g) for regular and 25 mg/g (fro-
zen: 23 mg/g) for decaffeinated coffee and trigonelline
concentrations were 8.7 mg/g (frozen: 8.7 mg/g) for reg-
ular and 7.4 mg/g (frozen: 7.1 mg/g) for decaffeinated
coffee. Therefore, the 5 daily cups of caffeinated coffee
provided 345 mg caffeine, 302 mg chlorogenic acid, and
78 mg trigonelline. Five cups of decaffeinated coffee
provided 216 mg chlorogenic acid and 65 mg
trigonelline.
Measurements
At the baseline, 4-week and 8-week visits, participants
wearing light clothing and no shoes had weight, height
and waist circumference measured by a trained investi-
gator. Waist circumference was measured half way
between the iliac crest and the lower border of the ribc-
age. Body composition was measured using Tanita
(model Quantum II, Lean Body software, RJL Systems,
Clinton Township, MI, US) single frequency bioelectri-
cal impedance analysis. Blood pressure was measured
under fasting conditions using a validated oscillometric
device with appropriately sized cuffs (Dinamap Pro100,
Critikon, Tampa, FL). At each assessment, 3 blood pres-
sure readings, taken in intervals of five minutes, were
averaged.
An intravenous cannula was placed in the antecubital
fossa and blood samples were collected after fasting for
at least 12 hours. Subsequently, participants consumed
75 grams of glucose (7.5 ounces of glucola) and blood
samples were taken at 30, 60 and 120 minutes. Glu-
cose was measured by glucose hexokinase method and
lipids using an autoanalyzer in the central clinical
laboratory at the Beth Israel Deaconess Medical Cen-
ter. All other samples were stored in a liquid nitrogen
freezer at < -130°C until assayed in duplicate with all
samples for the same participant included in the same
batch. Double-antibody radioimmunoassay (Immulite
®
Chemiluminescence, Siemens Co., New York, NY, US)
was used to measure insulin [intra-assay coefficient of
variation (CV) 2.1%], C-reactive protein (CRP) (CV
3.6%), and IL-6 (CV 4.7%). Adiponectin (CV 3.9%) and
fetuin-A (CV 2.4%) levels were measured by enzyme
linked immunosorbent assay kits (Millipore Corpora-
t i o n ,B i l l e r i c a ,M A ,U Sa n dA l p c o ,S a l e m ,N H ,U S ,
respectively).
At the 6-week visit, a non-fasting blood sample was
taken for measurement of serum caffeine levels. Plasma
concentrations of caffeine and metabolites (i.e., theobro-
mine, paraxanthine, theophylline) were determined by
high-performance liquid chromatography at the Tufts
University School of Medicine with within- and
between-assay CVs of 9% or lower.
Statistical Analysis
We compared the differences in change in biomarkers
from baseline to the 8-week visit between the treatment
groups using an analysis of covariance model. The model
included the change from baseline as the dependent vari-
able with treatment group as a main effect and baseline
values of the dependent variable as an additional covari-
ate. Weight change from baseline was also included as a
covariate. Differences between treatment groups were
based on linear contrasts for (1) caffeinated versus no
coffee, (2) decaffeinated versus no coffee, and (3) caffei-
nated versus decaffeinated coffee. The adjusted mean
with standard error was reported by treatment, and 95%
confidence intervals (CIs) were computed. Statistical sig-
nificance was evaluated at an alpha level of 0.05.
G l u c o s ea n di n s u l i na r e au n d e rt h ec u r v e( A U C )
values during the OGTT were calculated using the tra-
pezoidal rule [18]. The composite insulin sensitivity
index (CISI) was calculated using the formula: [10,000/
the square root of (fasting glucose × fasting insulin) ×
(mean glucose × mean insulin)] [19]. The homeostasis
model assessment for insulin resistance (HOMA-IR) was
calculated as [(fasting glucose × fasting insulin)/22.5]
[20]. The ratio between the 30 minute increment in
insulin to 30 minute increment in glucose concentration
(insulinogenic index) was used as a measure of early
insulin secretion. Variables with obvious departures
from normality were log-transformed, then converted
back to their original scale to yield geometric means
and associated 95% CIs. Normality was achieved for
these variables after log-transformation. For log-trans-
formed variables, mean differences between groups yield
a ratio given the principles of logged numbers and dif-
ferences for log-transformed variables are therefore pre-
sented as percentages.
Statistical analysis was performed using the last-obser-
vation-carried-forward method for imputation of miss-
ing values. One observation was carried forward from
the Week 4 visit, except for fetuin-A which was not
measured at week four. The final Week 8 analysis was
based on 41 participants as three participants discontin-
ued after baseline and one participant had a missing
value for change from baseline in weight. For glucose
homeostasis measurements, data were based on 40 par-
ticipants because one participant additionally had a
missing value for fasting glucose. Outliers for the out-
come variables were identified using a criterion of ±
three times the interquartile range. We performed sensi-
tivity analyses to test differences between the treatment
groups in changes in risk factors after outliers were
removed. Because results remained essentially the same
as for the main analysis and statistically significant dif-
ferences remained significant, we only present results
without removal of outliers. Spearman correlation
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markers of glucose metabolism were calculated at base-
line, as well as correlating changes over the 8-week
intervention period. All statistical analyses were per-
formed using SAS.
Results
The mean age of participants was 40 years and the
mean BMI 29.5 kg/m
2. Table 1 shows the baseline
characteristics of the participants according to group
allocation. Except for the lower IL-6 and CRP concen-
trations in the caffeinated coffee group, there were no
substantial differences between the groups. Correlation
coefficients for adiponectin, CRP, IL-6 and fetuin-A
concentrations with markers of glucose homeostasis at
baseline are shown in Table 2. Forty-one participants
(91%) completed the 8-week intervention period. The
intervention did not result in significant differences
Table 1 Baseline characteristics and clinical measurements for study participants by treatment group
Caffeinated Coffee Decaffeinated Coffee No Coffee
(N = 16) (N = 14) (N = 15)
Age (years) 38.7 (7.3) 41.9 (14.6) 41.2 (17.4)
Sex (% female) 11 (68.8) 9 (64.3) 9 (60.0)
Usual caffeinated coffee intake (mL/d) 998 (432) 885 (509) 758 (500)
Ethnicity
(% non-Hispanic white)
10 (62.5) 10 (71.4) 10 (66.7)
Physical activity
(MET-hrs/wk)
28.5 (31.6) 37.1 (35.4) 31.6 (18.0)
Weight (kg) 79.8 (10.7) 86.5 (9.3) 84.6 (11.4)
Body mass index (kg/m
2) 29.0 (2.3) 29.5 (2.2) 30.0 (2.4)
Waist circumference (cm)
Men 97.7 (7.3) 102.5 (7.3) 102.6 (6.3)
Women 85.2 (10.3) 90.9 (7.8) 88.3 (7.4)
Fat mass (%)
a 32.0 (7.5) 33.5 (8.9) 34.3 (6.6)
Glucose (mmol/L)
b
Fasting 4.8 (0.5) 4.9 (1.0) 4.7 (0.4)
2-hour 5.8 (1.8) 5.7 (1.6) 6.2 (1.6)
Area under the curve 13.2 (2.4) 13.3 (3.6) 14.0 (2.1)
Insulin (pmol/L)
Fasting 48.4 (33.6) 71.7 (50.9) 52.6 (21.1)
2-hour 288.7 (132.6) 381.1 (223.3) 366.4 (180.0)
Area under the curve 574. 2 (317.7) 717.8 (395.7) 675.1 (275.3)
CISI (mmol/L
-1*pmol/L
-1) 24.2 (15.4) 20.8 (15.7) 17.2 (7.4)
Insulin 30 min/Glucose 30 min 86.7 (59.2) 163.9 (162.4) 118.8 (89.6)
HOMA-IR 1.7 (1.1) 2.5 (2.0) 1.9 (0.8)
Adiponectin (μg/mL) 7.8 (4.8) 7.1 (3.7) 8.6 (3.6)
C-reactive protein (mg/L) 1.2 (1.0) 4.6 (5.8) 2.8 (3.2)
Interleukin-6 (pg/mL) 1.0 (0.5) 2.6 (2.6) 2.0 (1.3)
Fetuin-A (μg/mL) 246.1 (45.3) 270.7 (37.4) 280.2 (56.9)
HDL-cholesterol (mmol/L) 1.5 (0.4) 1.5 (0.5) 1.5 (0.3)
LDL-cholesterol (mmol/L) 2.8 (0.9) 2.4 (0.8) 2.3 (0.7)
Triglycerides (mmol/L) 1.1 (0.7) 1.0 (0.4) 1.0 (0.5)
Systolic blood pressure (mmHg) 115.0 (10.6) 119.7 (13.8) 121.3 (10.7)
Diastolic blood pressure (mmHg) 69.8 (7.6) 71.8 (5.8) 73.2 (8.7)
Heart rate (beats per minute) 68.0 (8.2) 71.3 (10.4) 66.5 (9.3)
Unless otherwise noted, data are means (standard deviation) for continuous variables and number (percentages) for categorical variables.
CISI, composite insulin sensitivity index. HOMA, homeostasis model assessment; IR, insulin resistance, HDL, high density lipoprotein; LDL, low density lipoprotein.
a Assessed by bioelectric impedance analysis.
b One participant missing baseline fasting glucose measurement (Decaffeinated coffee treatment group).
Wedick et al. Nutrition Journal 2011, 10:93
http://www.nutritionj.com/content/10/1/93
Page 4 of 9between treatment groups in body composition, diet,
physical activity, and sleep duration (Additional file 1,
table s1). To assess compliance, caffeine concentrations
were measured in non-fasting blood collected during the
6-week visit. Participants were unaware that caffeine was
being measured at this visit. Caffeine concentrations
were 3.1, 0.3, and 0.2 μg/mL for the caffeinated coffee,
decaffeinated coffee, and no coffee group, respectively
(p-value < 0.0001) and similar differences were found
for caffeine metabolites (Additional file 1, figure s2).
Table 3 shows the differences in biomarkers between
treatment groups at the end of the intervention adjusted
for baseline values and change in weight. Compared
with consuming no coffee, consumption of caffeinated
coffee and decaffeinated coffee was not significantly
associated with changes in glucose AUC (caffeinated:
-0.78 mmol/L; 95% CI: -2.52, 0.95; decaffeinated: 0.47
mmol/L; 95% CI: -1.40, 2.33) or 2-hour plasma glucose
(caffeinated: -0.41 mmol/L; 95% CI: -1.64, 0.83; decaffei-
nated: 0.79 mmol/L; 95% CI: -0.58, 2.16).
As compared with consuming no coffee, consump-
tion of caffeinated coffee significantly increased adipo-
nectin (difference in change from baseline 1.44 μg/mL;
95% CI: 0.23, 2.66) and IL-6 (60%; 95% CI: 8, 138),
whereas the decrease in fetuin-A (-11%; 95% CI: -27,
9) was not statistically significant. Changes after decaf-
feinated coffee consumption as compared with no cof-
fee were in the same direction and reached
significance for fetuin-A (-20%; 95% CI: -35, -1), but
not for adiponectin (0.91 μg/mL; 95% CI: -0.42, 2.25)
and IL-6 (37%; 95% CI: -8, 103). We did not find sig-
nificant differences for CRP and measures of insulin
resistance or insulin secretion.
In a secondary analysis evaluating blood pressure and
blood lipids (Table 3), participants using decaffeinated
coffee had a reduction in blood pressure as compared
with those consuming no coffee, which was statistically
significant for diastolic blood pressure (systolic: -3.1
mmHg, 95% CI: -11.6, 5.3; diastolic: -5.7 mmHg, 95%
CI: -10.9, -0.6). For caffeinated coffee, a small non-sig-
nificant increase in blood pressure was found as com-
pared with no coffee (systolic 1.2 mmHg, 95% CI: -6.5,
8.9; diastolic: 0.4 mmHg, 95% CI: -4.3, 5.2). There were
no significant differences between treatment groups for
high-or low density lipoprotein cholesterol, or fasting
triglyceride concentrations.
The changes from baseline at Week 4 and Week 8 for
a d i p o n e c t i na r es h o w ni nF i g u r e1 .I na ne x p l o r a t o r y
analysis using the complete study population regardless
of treatment group, changes in adiponectin levels during
the trial were significantly associated with changes in 2-
hour plasma glucose (b =- 0 . 3 7m m o l / L ,s . e .=0 . 1 3 ,p -
value = 0.009) (Additional file 1, figure s3)a n dg l u c o s e
AUC (b = -0.40 mmol/L, s.e. = 0.20, p-value = 0.043).
Changes in IL-6 and fetuin-A were not significantly
associated with changes in measures of glucose
metabolism.
During the 2-week caffeine washout period prior to
randomization, 15 occurrences of headaches were
reported and after the baseline visit two occurrences of
headaches were reported (one in the decaffeinated
group and one in the control group). There were a total
of four other adverse events reported during the trial
that were non-serious and consisted of a urinary tract
infection and gastroesophageal reflux among partici-
pants assigned to decaffeinated coffee, and a
Table 2 Correlation coefficients for adiponectin, C-reactive protein, interleukin-6, and fetuin-A concentrations and
markers of glucose metabolism at baseline
Adiponectin (μg/mL) C-reactive Protein (mg/L)
a Interleukin-6 (pg/mL)
a Fetuin-A (μg/mL)
a
Glucose (mmol/L)
b
Fasting
a -0.29 0.15 0.004 0.11
2-hour -0.25 0.16 0.20 0.26
Area under the curve -0.22 0.13 0.05 0.02
Insulin (pmol/L)
Fasting
a -0.06 0.23 0.17 0.33
c
2-hour
a -0.21 0.30 0.43
c 0.30
Area under the curve -0.17 0.22 0.43
c 0.31
c
CISI (mmol/L
-1 * pmol/L
-1)
a 0.13 -0.26 -0.27 -0.33
c
Insulin30 min/Glucose30 min
b -0.11 0.06 0.40
c 0.24
HOMA-IR
b -0.04 0.22 0.15 0.34
c
Spearman correlation coefficients have been adjusted for age, sex, and baseline BMI.
CISI, composite insulin sensitivity index; HOMA, homeostasis model assessment.
a Values were log transformed due to significant departures from normality.
b One participant missing baseline fasting glucose measurement (Decaffeinated coffee treatment group).
c P-value < 0.05.
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assigned to caffeinated coffee.
Conclusions
In this 8-week randomized trial of overweight men and
women, adiponectin and IL-6 levels increased for the
caffeinated coffee group as compared with the group
receiving no coffee. Fetuin-A levels decreased for decaf-
feinated coffee as compared with no coffee at the end of
the intervention. There were no significant differences
between the three treatment groups for CRP or mea-
sures of glucose metabolism.
Our results for adiponectin are consistent with one
observational study and non-randomized trial that found
higher adiponectin concentrations with increasing coffee
consumption [8,10]. The effects of coffee on fetuin-A
concentrations in our trial are consistent with the bene-
ficial effects of coffee on liver function suggested by
cross-sectional studies of coffee consumption and liver
enzymes [9]. The lack of significant effects of coffee
consumption on glucose tolerance may seem inconsis-
tent with the effect of coffee consumption on adiponec-
tin levels and the association between increases in
adiponectin levels and improvements in glucose toler-
ance in our study. However, we hypothesize that the
effect of coffee on glucose tolerance mediated by adipo-
nectin levels was too modest for a study of the current
sample size to detect. Possibly, long-term increases in
adiponectin and reductions in fetuin-A concentrations
contribute to the observed association between habitual
coffee consumption and a lower risk of T2DM [1,2].
In short-term studies, caffeinated coffee intake has
been associated with an acute reduction in insulin sensi-
tivity and glucose tolerance [3,21,22]. Caffeine may
reduce insulin sensitivity through adenosine receptor
antagonism, or by crossing the blood-brain barrier and
stimulating epinephrine release [1]. However, tolerance
to these effects of caffeine may develop after longer-
Table 3 Risk factors for type 2 diabetes by coffee treatment group at Week 8
a
Adjusted means at Week 8
value (95% CI)
Caffeinated Coffee Decaffeinated Coffee No Coffee
Glucose (mmol/L)
Fasting
† 4.97 (4.58, 5.40) 5.07 (4.60, 5.58) 4.78 (4.37, 5.22)
2-hour 5.48 (4.66, 6.30) 6.67 (5.72, 7.62) 5.88 (4.98, 6.78)
Area under the curve 13.07 (11.93, 14.20) 14.32 (13.00, 15.64) 13.85 (12.62, 15.08)
Insulin (pmol/L)
Fasting
b 47.53 (35.29, 64.03) 62.84 (44.69, 88.37) 48.81 (35.28, 67.54)
2-hour
b 255.15 (197.46, 329.70) 369.50 (275.80, 495.05) 312.99 (236.37, 414.46)
Area under the curve 617.99 (464.14, 771.83) 771.03 (594.83, 947.23) 697.47 (530.22, 864.72)
CISI (mmol/L
-1 * pmol/L
-1)
b 17.02 (13.25, 21.86) 12.38 (9.26, 16.53) 16.75 (12.78, 21.94)
Insulin30 min/Glucose30 min
b 113.78 (80.96, 159.91) 118.24 (79.65, 175.53) 78.77 (54.70, 113.43)
HOMA-IR
b 1.74 (1.23, 2.46) 2.33 (1.55, 3.49) 1.69 (1.16, 2.46)
Adiponectin (μg/mL) 8.90 (8.10, 9.71)
c 8.37 (7.44, 9.30) 7.46 (6.58, 8.34)
C-Reactive protein (mg/L)
b 1.63 (1.07, 2.47) 1.21 (0.76, 1.91) 1.24 (0.80, 1.92)
Interleukin-6 (pg/mL)
b 1.95 (1.50, 2.54)
c 1.67 (1.25, 2.22) 1.22 (0.93, 1.59)
Fetuin-A (μg/mL)
b 261.52 (228.83, 298.84) 233.71 (201.54, 270.99)
c 291.07 (212.94, 333.94)
HDL-cholesterol (mmol/L) 1.44 (1.36, 1.53) 1.39 (1.29, 1.49) 1.49 (1.40, 1.59)
LDL-cholesterol (mmol/L) 2.67 (2.46, 2.87) 2.50 (2.27, 2.73) 2.72 (2.50, 2.94)
Triglycerides (mmol/L)
b 0.93 (0.78, 1.11) 0.99 (0.81, 1.22) 0.99 (0.81, 1.20)
Systolic blood pressure (mmHg) 120.57 (115.46, 125.67) 116.23 (110.39, 122.07) 119.37 (113.80 124.95)
Diastolic blood pressure (mmHg) 72.82 (69.70, 75.95) 66.69 (63.10, 70.27)
c 72.42 (68.99, 75.84)
Heart rate (beats per minute) 67.77 (64.27, 71.26) 67.39 (63.36, 71.41) 67.63 (63.82, 71.45)
Adjusted means and associated 95% CIs were determined from analysis of covariance procedures. All models included treatment as a main effect, and baseline
value and change in weight as covariates.
CI, confidence interval; CISI, composite insulin sensitivity index. HOMA, homeostasis model assessment; IR, insulin resistance; HDL, high density lipoprotein; LDL,
low density lipoprotein.
a Results for the Week 8 analysis were based on last-observation-carried-forward method for imputation of missing values. One observation carried forward from
Week 4 visit, except fetuin-A not measured at Week 4. The Week 8 analysis was based on 41 participants, except for analysis of glucose tolerance measurements
(n = 40) where one participant had a missing value for fasting glucose.
b Original values were log transformed due to significant departures from normality, then back transformed to yield the geometric means and associated
confidence intervals.
c Significant difference compared to No Coffee (p < 0.05).
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source of other phytochemicals such as chlorogenic acid
and trigonelline, which may improve glucose metabo-
lism through beneficial effects on oxidative stress, gluco-
neogenesis, gut hormones, or intestinal microflora [23].
In a randomized trial in healthy men, intake of the cof-
fee components chlorogenic acid and trigonelline
acutely reduced glucose and insulin levels 15 minutes
after the oral glucose tolerance test [24]. Our findings
suggest that the acute detrimental effects of caffeinated
coffee on insulin sensitivity and glucose tolerance do
not remain after 8 weeks of coffee consumption. In con-
trast to our results, four weeks of very high caffeinated
coffee consumption (70 g coffee grounds) increased fast-
ing insulin concentrations which may reflect the higher
caffeine dose in that study [4].
Consistent with results from a previous trial [10], we
did not find effects of coffee consumption on CRP
levels. In contrast, cross-sectional studies have reported
both direct or inverse associations between coffee con-
sumption and CRP levels [8,25-27]. We found higher
IL-6 levels for the caffeinated coffee group as compared
with the group that drank no coffee, which is consistent
with results from a cross-sectional study in Greece [25].
However, high coffee consumption did not increase IL-6
production in a previous trial in humans [10]. In our
study, variation in IL-6 levels was large and baseline IL-
6 levels differed between groups with low levels in the
caffeinated coffee group. These limitations and the
inconsistent results across studies suggest that the
effects of coffee consumption on IL-6 concentrations
require further study.
In a secondary analysis, caffeinated coffee consump-
tion led to a non-significant 1.2 mmHg increase in sys-
tolic blood pressure and caffeinated and decaffeinated
coffee did not affect blood lipids consistent with pre-
vious meta-analyses [28,29]. Decaffeinated coffee con-
sumption reduced diastolic blood pressure as compared
with no coffee consumption, an effect that has not been
found in previous trials and requires further research
[29].
Our study has several limitations that need to be con-
sidered. First, although all coffee treatment groups were
blinded to the study investigators, the nature of the
intervention made it impossible to completely blind the
intervention assignment to the participants. Second,
compliance is a concern for trials in free-living indivi-
duals. However, more than 90% of the participants
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Page 7 of 9completed the intervention and based on the partici-
pants’ caffeine levels, compliance was high. Finally, a key
limitation that may have precluded our ability to detect
significant differences between the treatment groups was
the modest sample size. Our results warrant the conduct
of a larger long-term trial of effects of coffee on biomar-
kers of T2DM.
R e s u l t sf r o mc o h o r ts t u d i e ss u g g e s tt h a tc o f f e ec o n -
sumption may reduce risk of T2DM. This study contri-
butes to the current body of knowledge on mechanisms
that may underlie this association using a randomized
study design with an 8-week intervention and measure-
ment of novel metabolic markers. Our findings suggest
that improvements in adipocyte and liver function as
indicated by changes in adiponectin and fetuin-A levels
may contribute to beneficial metabolic effects of long-
term coffee consumption. Given the popularity and
widespread consumption of coffee, the effects of coffee
and coffee components on metabolic risk factors war-
rant further investigation.
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Figure S2, Figure S3 and Table S1. Figure S1. Flow of participants
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standard error values for caffeine and metabolites concentrations.
Regular coffee (n = 14), Decaffeinated coffee (n = 13), No coffee (n =
14).; Figure S3. Association between change in adiponectin
concentrations and change in 2-hour glucose concentrations during the
study. Shown is a scatterplot of participant values for change from
baseline at Week 8 in 2-hour glucose versus change in adiponectin
including the simple linear regression line.; and Table S1. Body
composition, lifestyle, and diet by coffee treatment group at baseline
and the end of the trial.
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